Ipsen S.A.

LSE:0MH6 Stock Report

Market Cap: €9.1b

Ipsen Past Earnings Performance

Past criteria checks 1/6

Ipsen has been growing earnings at an average annual rate of 19.8%, while the Pharmaceuticals industry saw earnings declining at 2.5% annually. Revenues have been growing at an average rate of 6.6% per year. Ipsen's return on equity is 8.5%, and it has net margins of 10%.

Key information

19.8%

Earnings growth rate

19.9%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate6.6%
Return on equity8.5%
Net Margin10.0%
Next Earnings Update31 Jul 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ipsen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0MH6 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 243,5753561,174687
30 Jun 243,4356641,157653
31 Mar 243,3716411,146636
31 Dec 233,3066171,135619
30 Jun 233,2824061,105528
31 Mar 233,2195001,072487
31 Dec 223,1565931,039445
30 Sep 223,0536561,007436
30 Jun 222,950719975427
31 Mar 222,849675946425
31 Dec 212,749631916424
30 Sep 212,712626923422
30 Jun 212,676622931420
31 Mar 212,681585951413
31 Dec 202,686548972406
30 Sep 202,697249986404
30 Jun 202,707-501,000403
31 Mar 202,700-531,010396
31 Dec 192,693-551,021389
30 Sep 192,6051761,003363
30 Jun 192,516406986337
31 Mar 192,432397970319
31 Dec 182,348388954302
30 Sep 182,258365931292
30 Jun 182,167343909281
31 Mar 182,090307883274
31 Dec 172,012270858266
30 Sep 171,923243821264
30 Jun 171,834217785262
31 Mar 171,753221752247
31 Dec 161,671226719231
30 Sep 161,623229703214
30 Jun 161,575233687196
31 Mar 161,548211676194
31 Dec 151,520189666193
30 Sep 151,468165651192
30 Jun 151,416140636191
31 Mar 151,374147606189
31 Dec 141,332154577187
30 Sep 141,310155557190
30 Jun 141,287156537193
31 Mar 141,284149543194

Quality Earnings: 0MH6 has a large one-off loss of €295.0M impacting its last 12 months of financial results to 31st December, 2024.

Growing Profit Margin: 0MH6's current net profit margins (10%) are lower than last year (18.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0MH6 has become profitable over the past 5 years, growing earnings by 19.8% per year.

Accelerating Growth: 0MH6's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 0MH6 had negative earnings growth (-42.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.1%).

Return on Equity

High ROE: 0MH6's Return on Equity (8.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 09:00
End of Day Share Price 2025/02/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ipsen S.A. is covered by 34 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles Pitman-KingBarclays
Richard SilverBarclays
Hae Won NaBerenberg